Anglo-Indian licensing agreement for meningitis-B vaccine

In a significant stride towards addressing the challenge of meningococcal-B disease, Serum Institute of India (SII) and the University of Oxford, UK, have formalized a technology license agreement negotiated by Oxford University Innovation.

They say the partnership will deliver lifesaving protection against Men-B through the production of a chimeric protein-based vaccine. The agreement underscores the shared institutional commitment to combat disease caused by Neisseria meningitidis and represents a proactive response to overcome the limitations of currently available Men-B vaccines in terms of efficacy, safety, and coverage.

"The Men-B vaccine agreement with the Serum Institute of India is another example of vaccine innovation at the University of Oxford. Oxford’s commitment and investment to develop efficacious, deployable vaccines will protect millions of lives and academic licensing and successful commercial partnerships that help solve global health challenges," said Simon Warner, head of licensing and ventures, life sciences, Oxford University Innovation.